A Study to Evaluate Whether Correction of Anemia Using Recombinant Human Erythropoietin Reduces the Progression of Atherosclerosis and Cardiac Hypertrophy in Pre-dialysis Chronic Kidney Disease Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The primary aim of the study is to evaluate the effects of correction of anemia using erythropoietin on the progression of atherosclerosis and cardiac muscle thickening in patients with chronic kidney disease
A Prospective Randomised Controlled Trial to Study the Effects of Recombinant Human Erythropoietin on the Progression of Atherosclerosis, Cardiovascular Function, Nutrition and Residual Renal Function in Pre-dialysis Chronic Renal Failure Patients
Study Start Date :
Actual Study Completion Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
up to 75 Years (Child, Adult, Senior)
Sexes Eligible for Study:
Patients with chronic renal failure with serum creatinine between 150umol/L and 800umol/L and at the same time Hb
Patients with regression line of 1/serum creatinine versus time showing that they may not require dialysis within the coming 12 months
Patients below the age of 75
Patients with valvular heart disease/congenital heart disease
Patients with ischemic heart disease/history of myocardial infarction/coronary artery bypass surgery
Patients with history of heart failure
Patients with regression line of 1/serum creatinine versus time showing that the estimated date of end stage renal disease is within 12 months
Patients with thalassemic trait or haemoglobinopathies
Patients with underlying haematological malignancies
Patients with active bleeding
Patients with uncorrected iron or other vitamins deficiencies